Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06131437 · ClinicalTrials.gov registry record · Phase 3
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 809
- Enrollment target
NCT06131437 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 809 participants.
The verdict
NCT06131437, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 809 participants
- Enrollment target
Study Summary
This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide. CagriSema is not yet being prescribed by doctors. Participant will get injections once a week throughout the treatment period. Participant will inject the study medicine under the skin with a pen injector in the thigh, stomach, or upper arm. After a first low dose, the study medicine will be gradually increased until reaching the planned dose (2.4 mg CagriSema or 15 mg Tirzepatide). The study will last for about one and a half year for each participant.
Interventions
- DRUG Tirzepatide
- DRUG Semaglutide
- DRUG Cagrilintide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 809 participants |
| Start Date | 2023-11-27 |
| Est. Completion | 2026-01-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06131437
The ClinicalTrials.gov registry entry for NCT06131437 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 809 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tirzepatide is the first listed.
NCT06131437 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06131437 about?
NCT06131437 is a clinical study titled "A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight". This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide. CagriSema is not yet being prescribed by doctors. Participant will get injections...
What is the current status of trial NCT06131437?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 809 participants. The study started on 2023-11-27. Estimated completion is 2026-01-09.
What interventions are being tested in trial NCT06131437?
The interventions under investigation include: Tirzepatide (DRUG), Semaglutide (DRUG), Cagrilintide (DRUG).
Who is sponsoring clinical trial NCT06131437?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.